iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Hits New 52-Week High – Here’s Why

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $102.57 and last traded at $102.57, with a volume of 1060 shares changing hands. The stock had previously closed at $100.25.

iShares U.S. Pharmaceuticals ETF Stock Performance

The firm has a market cap of $1.18 billion, a PE ratio of 17.75 and a beta of 0.49. The company’s 50-day simple moving average is $92.64 and its two-hundred day simple moving average is $89.15.

Hedge Funds Weigh In On iShares U.S. Pharmaceuticals ETF

Several hedge funds and other institutional investors have recently modified their holdings of IHE. EFG International AG bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the fourth quarter worth about $38,000. O Shaughnessy Asset Management LLC raised its position in iShares U.S. Pharmaceuticals ETF by 35.0% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 463 shares of the company’s stock valued at $39,000 after purchasing an additional 120 shares during the last quarter. Assetmark Inc. lifted its holdings in iShares U.S. Pharmaceuticals ETF by 203.9% in the 4th quarter. Assetmark Inc. now owns 465 shares of the company’s stock worth $39,000 after buying an additional 312 shares during the period. Blueline Advisors LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF in the 4th quarter worth approximately $41,000. Finally, Accent Capital Management LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 4th quarter worth approximately $42,000.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.